Record overview
Status and phase
Status: COMPLETED
Phase: PHASE2
Sponsor: Seoul National University Hospital
Condition: Relapsed or Refractory EBV-and CD30-positive Lymphomas
NCT02388490
Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: None
Stopped reason
Context when available
No stop reason available in the current public record.